FFA
BCRX icon

Farther Finance Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Farther Finance Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.8K Buy
6,551
+861
+15% +$7.79K ﹤0.01% 3042
2026
Q1 		$53.4K Sell
5,690
-5,802
-50% -$45.1K ﹤0.01% 2956
2025
Q4 		$89.6K Buy
11,492
+902
+9% +$6.52K ﹤0.01% 2413
2025
Q3 		$80.4K Buy
10,590
+8,109
+327% +$67.5K ﹤0.01% 2166
2025
Q2 		$22.2K Buy
2,481
+19
+0.8% +$177 ﹤0.01% 2613
2025
Q1 		$17.9K Buy
+2,462
New +$19.9K ﹤0.01% 2443
2024
Q2 		– Sell
-60
Closed -$303 – 3830
2024
Q1 		$303 Buy
+60
New +$337 ﹤0.01% 3162

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Farther Finance Advisors's BCRX Position: Q2 2026 in Review

Farther Finance Advisors increased its BioCryst Pharmaceuticals (BCRX) stake by 15% in Q2 2026, buying an estimated $7.79K and bringing the position to 6,551 shares worth $64.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3042.

Farther Finance Advisors first reported a position in BCRX in Q1 2024 and has held it in 7 quarters since. The position peaked at $89.6K in Q4 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Farther Finance Advisors held 6,551 shares of BioCryst Pharmaceuticals worth $64.8K as of Q2 2026.
  • Farther Finance Advisors bought 861 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $7.79K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #3042 holding.
  • Farther Finance Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
  • Farther Finance Advisors's BioCryst Pharmaceuticals position peaked at $89.6K in Q4 2025.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.